Document:

<PAGE>

                                                                     EXHIBIT 4.2

                          REGISTRATION RIGHTS AGREEMENT

                  This REGISTRATION RIGHTS AGREEMENT (this "Agreement") is
entered into as of __________, 2003 by and among Stratagene Corporation, a
Delaware corporation formerly known as Stratagene Holding Corporation
("Stratagene"), and Joseph A. Sorge ("Sorge"), the J. A. Sorge Trust I, the J.
A. Sorge Trust II, the J. A. Sorge Trust III, the J. A. Sorge Trust IV, Biosense
Partners, L.P. and the Joseph A. Sorge Charitable Remainder Trust dated December
26, 2002 (collectively, the "Sorge Entities").

                                    RECITALS

                  WHEREAS, Stratagene, SHC Acquisition Sub, Inc., a Delaware
corporation and a wholly owned subsidiary of Stratagene ("Merger Sub"), and
Hycor Biomedical Inc., a Delaware corporation ("Hycor"), previously entered into
that certain Agreement and Plan of Reorganization, dated as of July 24, 2003
(the "Merger Agreement"); and

                  WHEREAS, in consideration of the Sorge Entities agreeing to
vote in favor of the Merger Agreement and recognizing the limited ability of the
Sorge Entities to sell their shares of Stratagene common stock, par value
$0.0001 per share (the "Common Stock"), following the merger contemplated by the
Merger Agreement, Stratagene agreed to enter into this Agreement to grant the
Sorge Entities certain registration and other rights with respect to the
Registrable Securities (as defined below).

                                    AGREEMENT

                  NOW, THEREFORE, in consideration of the promises and mutual
agreements contained herein, the parties hereto agree as follows:

                                   ARTICLE I.
                                   DEFINITIONS

         1.1      Definitions. As used herein, unless the context otherwise
requires, the following terms have the following respective meanings:

                  "Affiliate" means, with respect to any Person, any Person
that, directly or indirectly, controls, is controlled by or is under common
control with such Person. For the purposes of this definition, "control"
(including, with correlative meanings, the terms "controlled by" and "under
common control with"), as used with respect to any Person, shall mean the
possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such Person, whether through the
ownership of voting securities or by contract or otherwise.

                  "Certificate of Incorporation" means the Certificate of
Incorporation of Stratagene, as it may be amended or restated hereafter from
time to time.

                  "Common Stock" shall have the meaning set forth in the
recitals of this Agreement.

<PAGE>

                  "Effective Time" shall have the meaning set forth in the
Merger Agreement.

                  "Exchange Act" means the Securities Exchange Act of 1934, as
amended, or any similar or successor Federal statute, and the rules and
regulations of the SEC thereunder, all as the same shall be in effect at the
relevant time.

                  "Merger Agreement" shall have the meaning set forth in the
recitals of this Agreement.

                  "Permitted Transferee" means, with respect to any Sorge
Entity, any sale or other transfer to an Affiliate of such Sorge Entity and with
respect to Sorge, shall also mean any family member or trust for the benefit of
Sorge or any such family member.

                  "Person" means and includes an individual, a corporation, a
limited liability company, an association, a partnership, a trust or estate, a
government or any department or agency thereof.

                  "Principal Market" means either the Nasdaq National Market or
the Nasdaq SmallCap Market, or if the Common Stock is not then listed on either
of such markets, the principal market or exchange on which the Common Stock is
then listed or traded.

                  "Sorge Entities" shall have the meaning set forth in the
preamble of this Agreement.

                  "Registrable Securities" means (a) all shares of Common Stock
held by any Sorge Entity on the date hereof and (b) any other shares of Common
Stock issued by way of a stock dividend, stock split or reverse stock split or
in connection with a combination of shares, recapitalization, merger,
consolidation or similar event, with respect to or in exchange for or in
replacement of the shares listed in clause (a). As to any particular Registrable
Securities, such securities shall cease to be Registrable Securities when (i) a
registration statement covering such securities shall have become effective
under the Securities Act and such securities shall have been disposed of in
accordance with such registration statement, (ii) Rule 144 (or any successor
provision) under the Securities Act is available for the sale of all of the
Registrable Securities held by a Sorge Entity during any three (3)-month period
without registration (taking into account the holdings of all Sorge Entities) or
(iii) such securities shall have ceased to be outstanding.

                  "Registration Expenses" means all expenses incident to the
registration and disposition of the Registrable Securities pursuant to Section 2
hereof, including, without limitation, all registration, filing and applicable
national securities exchange fees, all fees and expenses of complying with state
securities or blue sky laws (including fees and disbursements of counsel to the
Sorge Entities in connection with "blue sky" qualification of the Registrable
Securities and determination of their eligibility for investment under the laws
of the various jurisdictions), all word processing, duplicating and printing
expenses, all messenger and delivery expenses, the fees and disbursements of
counsel for Stratagene and of its independent public accountants, including the
expenses of "cold comfort" letters or any special audits required by, or
incident to, such registration, all fees and disbursements of underwriters
(other than underwriting

                                       2
<PAGE>

discounts and commissions), and all reasonable fees and expenses of a single
counsel to the Sorge Entities and all holders of Registrable Securities. The
Registration Expenses shall not include the Selling Expenses.

                  "SEC" means the Securities and Exchange Commission or any
other governmental authority at the time administering the Securities Act or the
Exchange Act.

                  "Securities Act" means the Securities Act of 1933, as amended,
or any similar or successor Federal statute, and the rules and regulations of
the SEC thereunder, all as the same shall be in effect at the relevant time.

                  "Selling Expenses" means underwriting discounts, selling fees
and commissions and stock transfer taxes applicable to the Registrable
Securities, which shall be paid by the Sorge Entities.

                  "Sorge" shall have the meaning set forth in the preamble of
this Agreement.

                  "Sorge Entities" shall have the meaning set forth in the
preamble of this Agreement.

                  "Stratagene" shall have the meaning set forth in the preamble
of this Agreement.

                                  ARTICLE II.
                               REGISTRATION RIGHTS

         2.1      Filing of Registration Statement.

                  (a)      Registration. Within thirty (30) days following its
receipt of a written request from Sorge after the Effective Time, Stratagene
shall (i) use commercially reasonable efforts to file a registration statement
under the Securities Act on Form S-3, or on Form S-1 if Stratagene does not
qualify for Form S-3, covering 2,000,000 shares of Registrable Securities and
(ii) if requested by Sorge, use commercially reasonable efforts to obtain
acceleration of the effective date of the registration statement relating to
such registration.

                  (b)      Registration Statement Form. Subject to clause (a)(i)
above, the registration under this Section 2.1 shall be on such appropriate
registration form of the SEC as shall be selected by Stratagene and as shall be
reasonably acceptable to Sorge. Stratagene agrees to include in any such
registration statement all information which, in the opinion of counsel to Sorge
and counsel to Stratagene, is necessary or desirable to be included therein. If
such counsel disagree, the opinion of counsel to Stratagene shall be followed.

                  (c)      Expenses. Stratagene shall pay all Registration
Expenses in connection with the registration of Registrable Securities under
this Section 2.1.

         2.2      Incidental Registration.

                  (a)      Right to Include Registrable Securities. If
Stratagene at any time proposes to register any Common Stock for its own account
or for the account of any other stockholder

                                       3
<PAGE>

under the Securities Act by registration on Form S-1, S-2 or S-3 or any
successor or similar form(s) (except registrations on any such Form or similar
form(s) solely for registration of securities in connection with an employee
benefit plan, stock incentive or dividend reinvestment plan or a merger,
acquisition or consolidation or incidental to an issuance of securities under
Rule 144A under the Securities Act), Stratagene will give prompt written notice
to Sorge of its intention to do so and of each Sorge Entities' rights under this
Section 2.2 in connection with each such proposed registration. At any time or
from time to time after the Effective Time, upon the written request of Sorge
(which request shall specify the maximum number of Registrable Securities
intended to be disposed of by the Sorge Entities), made as promptly as
practicable and in any event within ten (10) days after the receipt of any such
notice, Stratagene shall use commercially reasonable efforts to effect the
registration under the Securities Act of all Registrable Securities which
Stratagene has been so requested to register by the Sorge Entities; provided,
however, that if at any time after giving written notice of their intention to
register any securities and prior to the effective date of the registration
statement filed in connection with such registration, Stratagene shall determine
for any reason not to register or to delay registration of such securities,
Stratagene shall give written notice of such determination and its reasons
therefor to Sorge and (i) in the case of a determination not to register, shall
be relieved of its obligation to register any Registrable Securities in
connection with such registration (but not from any obligation of Stratagene to
pay the Registration Expenses in connection therewith) and (ii) in the case of a
determination to delay registering, shall be permitted to delay registering any
Registrable Securities, for such period of time as the Board of Directors of
Stratagene determines. No registration effected under this Section 2.2 shall
relieve Stratagene of its obligation to effect the registration under Section
2.1.

                  (b)      Expenses. Stratagene shall pay all Registration
Expenses in connection with any registration requested pursuant to this Section
2.2.

                  (c)      Right to Withdraw. The Sorge Entities shall have the
right to withdraw their request for inclusion of their Registrable Securities in
any registration statement pursuant to this Section 2.2 at any time by giving
written notice to Stratagene of their request to withdraw.

                  (d)      Priority in Incidental Registrations. If the managing
underwriter of any underwritten offering shall inform Stratagene by writing of
its belief that the number of Registrable Securities requested to be included in
such registration, when added to the number of other securities to be offered in
such registration, would jeopardize such offering, then Stratagene shall include
in such registration, only that number of such securities, including Registrable
Securities, which the underwriter determines in its sole discretion will not
jeopardize the success of the offering (such securities to be included in the
following priority: (i) first, the securities proposed to be included by
Stratagene, (ii) second, the Registrable Securities requested by the Sorge
Entities to be included in such registration and (iii) third, any other
securities of Stratagene requested to be included in such registration by any
other holders having the right to include securities on a pro rata basis in
accordance with the number of securities proposed to be included by such other
holders). The Sorge Entities agree to reasonably modify this priority to
facilitate private placements by Stratagene or to facilitate the conversion of
Stratagene Notes (as defined in the Merger Agreement).

                                       4
<PAGE>

         2.3      Registration Procedures. When Stratagene effects the
registration of Registrable Securities under the Securities Act required by
Section 2.1 and if and whenever Stratagene is required to effect the
registration of any additional Registrable Securities under the Securities Act
as provided in Section 2.2 hereof, Stratagene shall as expeditiously as
possible:

                  (a)      prepare and file with the SEC as soon as practicable
the requisite registration statement to effect such registration (and shall
include all financial statements required by the SEC to be filed therewith) and
thereafter use commercially reasonable efforts to cause such registration
statement to become effective; provided, however, that before filing such
registration statement (including all exhibits) or any amendment or supplement
thereto or comparable statements under securities or blue sky laws of any
jurisdiction, Stratagene shall as promptly as practicable furnish such documents
to Sorge and each underwriter, if any, participating in the offering of the
Registrable Securities and their respective counsel, which documents will be
subject to the review and comments of the Sorge Entities, each underwriter and
their respective counsel;

                  (b)      notify Sorge of the SEC's requests for amending or
supplementing the registration statement and the prospectus; and prepare and
file with the SEC such amendments and supplements to such registration statement
and the prospectus used in connection therewith as may be necessary to keep such
registration statement effective and to comply with the provisions of the
Securities Act with respect to the disposition of all Registrable Securities
covered by such registration statement for a period of at least twenty four (24)
months or such shorter period as shall be required for the disposition of all of
such Registrable Securities in accordance with the intended method of
distribution thereof;

                  (c)      furnish, without charge, to Sorge and each
underwriter, if any, such number of conformed copies of such registration
statement and of each such amendment and supplement thereto (in each case
including all exhibits), such number of copies of the prospectus contained in
such registration statement (including each preliminary prospectus and any
summary prospectus) and any other prospectus filed under Rule 424 under the
Securities Act, in conformity with the requirements of the Securities Act, and
such other documents, as Sorge and such underwriters may reasonably request;

                  (d)      use commercially reasonable efforts (i) to register
or qualify all Registrable Securities and other securities covered by such
registration statement under such securities or blue sky laws of such states of
the United States of America where an exemption is not available and as Sorge or
any managing underwriter shall reasonably request, (ii) to keep such
registration or qualification in effect for so long as such registration
statement remains in effect and (iii) to take any other action which may be
reasonably necessary or advisable to enable Sorge to consummate the disposition
in such jurisdictions of the securities to be sold by the Sorge Entities, except
that Stratagene shall not for any such purpose be required to qualify generally
to do business as a foreign corporation in any jurisdiction wherein it would not
but for the requirements of this subsection (d) be obligated to be so qualified
or to consent to general service of process or subject itself to taxation in any
such jurisdiction;

                  (e)      use commercially reasonable efforts to cause all
Registrable Securities covered by such registration statement to be registered
with or approved by such other federal or

                                       5
<PAGE>

state governmental agencies or authorities as may be necessary in the opinion of
counsel to Stratagene and counsel to Sorge by virtue of the business and
operations of Stratagene to consummate the disposition of such Registrable
Securities;

                  (f)      in the case of any underwritten offering under
Section 2.2, cause to be furnished to Sorge and each underwriter, if any,
participating in the offering of the securities covered by such registration
statement, a signed counterpart of (i) an opinion of counsel for Stratagene and
(ii) a "comfort" letter signed by the independent public accountants who have
certified Stratagene's or any other entity's financial statements included or
incorporated by reference in such registration statement, covering substantially
the same matters with respect to such registration statement (and the prospectus
included therein) and, in the case of the accountants' comfort letter, with
respect to events subsequent to the date of such financial statements, as is
customarily covered in opinions of issuer's counsel and in accountants' comfort
letters delivered to the underwriters in underwritten public offerings of
securities (and dated the dates such opinions and comfort letters are
customarily dated) and, in the case of the legal opinion, such other legal
matters;

                  (g)      promptly notify the Sorge Entities and each managing
underwriter, if any, participating in the offering of the securities covered by
such registration statement (i) when such registration statement, any
pre-effective amendment, the prospectus or any prospectus supplement related
thereto or post-effective amendment to such registration statement has been
filed, and, with respect to such registration statement or any post-effective
amendment, when the same has become effective, (ii) of any request by the SEC
for amendments or supplements to such registration statement or the prospectus
related thereto or for additional information, (iii) of the issuance by the SEC
of any stop order suspending the effectiveness of such registration statement or
the initiation of any proceedings for that purpose, (iv) of the receipt by
Stratagene of any notification with respect to the suspension of the
qualification of any of the Registrable Securities for sale under the securities
or blue sky laws of any jurisdiction or the initiation of any proceeding for
such purpose, (v) at any time when a prospectus relating thereto is required to
be delivered under the Securities Act, upon discovery that, or upon the
happening of any event as a result of which, the prospectus included in such
registration statement, as then in effect, includes an untrue statement of a
material fact or omits to state any material fact required to be stated therein
or necessary to make the statements therein not misleading, in the light of the
circumstances under which they were made, and in the case of this clause (v), at
the request of Sorge, promptly prepare and furnish to Sorge and each managing
underwriter, if any, participating in the offering of the Registrable
Securities, a reasonable number of copies of a supplement to or an amendment of
such prospectus as may be necessary so that, as thereafter delivered to Sorge,
such prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances under which
they were made and (vi) in the case of an underwritten offering, at any time
when the representations and warranties of Stratagene contemplated by Section
2.4 hereof cease to be true and correct;

                  (h)      use commercially reasonable efforts to comply with
all applicable rules and regulations of the SEC, and make available to its
security holders, as soon as reasonably practicable, an earnings statement
covering a period of at least twelve months beginning with the first full
calendar month after the effective date of such registration statement, which
earnings

                                       6
<PAGE>

statement shall satisfy the provisions of Section 11(a) of the Securities Act
and Rule 158 promulgated thereunder;

                  (i)      provide and cause to be maintained a transfer agent
and registrar for all Registrable Securities covered by such registration
statement from and after a date not later than the effective date of such
registration;

                  (j)      use commercially reasonable efforts to cause all
Registrable Securities covered by such registration statement to be listed on
the Principal Market;

                  (k)      deliver promptly to counsel to Sorge and each
underwriter, if any, participating in the offering of the Registrable
Securities, copies of all correspondence between the SEC and Stratagene, its
counsel or auditors and all memoranda relating to discussions with the SEC or
its staff with respect to such registration statement;

                  (l)      use commercially reasonable efforts to obtain the
withdrawal of any order suspending the effectiveness of the registration
statement; and

                  (m)      provide a CUSIP number for all Registrable
Securities, no later than the effective date of the registration statement.

                  Stratagene may require Sorge to furnish Stratagene such
information regarding the Sorge Entities and the distribution of the Registrable
Securities as Stratagene may from time to time reasonably request in writing.

                  The Sorge Entities agree that upon receipt of any notice from
Stratagene of the happening of any event of the kind described in paragraph
(g)(iii) or (v) of this Section 2.3, the Sorge Entities will, to the extent
appropriate, discontinue their disposition of Registrable Securities pursuant to
the registration statement relating to such Registrable Securities until, in the
case of paragraph (g)(v) of this Section 2.3, their receipt of the copies of the
supplemented or amended prospectus contemplated by paragraph (g)(v) of this
Section 2.3 and, if so directed by Stratagene, will deliver to Stratagene (at
Stratagene's expense) all copies, other than permanent file copies, then in
their possession, of the prospectus relating to such Registrable Securities
current at the time of receipt of such notice. If the disposition by the Sorge
Entities of their securities is discontinued pursuant to the foregoing sentence,
Stratagene shall extend the period of effectiveness of the registration
statement by the number of days during the period from and including the date of
the giving of notice to and including the date when the Sorge Entities shall
have received copies of the supplemented or amended prospectus contemplated by
paragraph (g)(v) of this Section 2.3.

         2.4      Underwritten Offerings. In the case of a registration pursuant
to Section 2.2 hereof, if Stratagene shall have determined to enter into any
underwriting agreement in connection therewith, all of the Registrable
Securities to be included in such registration shall be subject to such
underwriting agreement. In such case, the Sorge Entities shall be party to such
underwriting agreement.

                                       7
<PAGE>

         2.5      Indemnification.

                  (a)      Indemnification by Stratagene. Stratagene agrees that
in the event of any registration of any of the Registrable Securities under the
Securities Act, Stratagene shall, and hereby does, indemnify and hold harmless
the Sorge Entities, their respective directors, officers, employees, members,
partners, agents and affiliates and each other Person who participates as an
underwriter in the offering or sale of such securities and each other Person, if
any, who controls any Sorge Entity or any such underwriter within the meaning of
the Securities Act, against any losses, claims, damages, or liabilities, joint
or several, to which the Sorge Entities or any such director, officer, employee,
member, partner, agent or affiliate or underwriter or controlling person may
become subject under the Securities Act or otherwise, insofar as such losses,
claims, damages or liabilities, joint or several (or actions or proceedings,
whether commenced or threatened, in respect thereof), arise out of or are based
upon (i) any untrue statement or alleged untrue statement of any material fact
contained in any registration statement under which such securities were
registered under the Securities Act, any preliminary prospectus, final
prospectus or summary prospectus contained therein, or any amendment or
supplement thereto, (ii) any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein in light of the circumstances in which they were made not misleading or
(iii) any violation by Stratagene of any Federal, state or common law rule or
regulation applicable to Stratagene and relating to action required of or
inaction by Stratagene in connection with any such registration, and Stratagene
shall reimburse the Sorge Entities and each such director, officer, employee,
member, partner, agent or affiliate, underwriter or controlling Person for any
reasonable legal or any other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, liability, action or
proceeding; provided, that Stratagene shall not be liable in any such case to
the Sorge Entities or any such director, officer, employee, member, partner,
agent or affiliate, underwriter or controlling Person to the extent that any
such loss, claim, damage, liability (or action or proceeding in respect thereof)
or expense arises out of or is based upon any untrue statement or alleged untrue
statement or omission or alleged omission made in such registration statement,
any such preliminary prospectus, final prospectus, summary prospectus, amendment
or supplement in reliance upon and in conformity with written information
furnished to Stratagene by or on behalf of the Sorge Entities, specifically
stating that it is for use in the preparation thereof. Such indemnity shall
remain in full force regardless of any investigation made by or on behalf of the
Sorge Entities or any such director, officer, employee, member, partner, agent
or affiliate, underwriter or controlling Person and shall survive the transfer
of such securities by the Sorge Entities. Such indemnity shall not extend to any
liability imposed on Sorge as an officer or director of Stratagene, which shall
be made only as permitted by law and by Stratagene's corporate policy.

                  (b)      Indemnification by the Sorge Entities. The Sorge
Entities agree that in the event of any registration of the Registrable
Securities under the Securities Act, the Sorge Entities shall, and hereby do,
indemnify and hold harmless (in the same manner and to the same extent as set
forth in paragraph (a) of this Section 2.5) Stratagene, and each director of
Stratagene, each officer, employee, agent and affiliate of Stratagene and each
other Person, if any, who controls Stratagene within the meaning of the
Securities Act, with respect to any statement or alleged statement in or
omission or alleged omission from such registration statement, any preliminary
prospectus, final prospectus or summary prospectus contained therein, or any
amendment or supplement thereto, but only to the extent such statement or
alleged statement or omission or

                                       8
<PAGE>

alleged omission was made in reliance upon and in conformity with written
information furnished to Stratagene by or on behalf of the Sorge Entities
specifically stating that it is for use in the preparation of such registration
statement, preliminary prospectus, final prospectus, summary prospectus,
amendment or supplement; provided, however, that the liability of the Sorge
Entities under this Section 2.5(b) shall be limited to the amount of proceeds
(net of expenses and underwriting discounts and commissions) received by the
Sorge Entities in the offering giving rise to such liability. Such indemnity
shall remain in full force and effect, regardless of any investigation made by
or on behalf of Stratagene or any such director, officer or controlling Person
and shall survive the transfer of such securities by the Sorge Entities.

                  (c)      Notices of Claims, etc. Promptly after receipt by an
indemnified party of notice of the commencement of any action or proceeding
involving a claim referred to in the preceding subsections of this Section 2.5,
such indemnified party shall, if a claim in respect thereof is to be made
against an indemnifying party, give written notice to the latter of the
commencement of such action or proceeding; provided, however, that the failure
of any indemnified party to give notice as provided herein shall not relieve the
indemnifying party of its obligations under the preceding subsections of this
Section 2.5, except to the extent that the indemnifying party is actually
prejudiced by such failure to give notice, and shall not relieve the
indemnifying party from any liability which it may have to the indemnified party
otherwise than under this Section 2.5. In case any such action or proceeding is
brought against an indemnified party, the indemnifying party shall be entitled
to participate therein and, unless in the opinion of outside counsel to the
indemnified party a conflict of interest between such indemnified and
indemnifying parties may exist in respect of such claim, to assume the defense
thereof, jointly with any other indemnifying party similarly notified to the
extent that it may wish, with counsel reasonably satisfactory to such
indemnified party; provided, however, that if the defendants in any such action
or proceeding include both the indemnified party and the indemnifying party and
if in the opinion of outside counsel to the indemnified party there may be legal
defenses available to such indemnified party and/or other indemnified parties
which are different from or in addition to those available to the indemnifying
party, the indemnified party or parties shall have the right to select separate
counsel to defend such action or proceeding on behalf of such indemnified party
or parties, provided, further, that the indemnifying party shall be obligated to
pay for only one counsel and one local counsel for all indemnified parties.
After notice from the indemnifying party to such indemnified party of its
election so to assume the defense thereof and approval by the indemnified party
of such counsel, the indemnifying party shall not be liable to such indemnified
party for any legal expenses subsequently incurred by the latter in connection
with the defense thereof other than reasonable costs of investigation (unless
the first proviso in the preceding sentence shall be applicable). No
indemnifying party shall be liable for any settlement of any action or
proceeding effected without its written consent. No indemnifying party shall,
without the consent of the indemnified party (which consent shall not be
unreasonably withheld or delayed), consent to entry of any judgment or enter
into any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such indemnified party of a release from
all liability in respect of such claim or litigation.

                  (d)      Contribution. If the indemnification provided for in
this Section 2.5 shall for any reason be held by a court to be unavailable to an
indemnified party under subsection (a) or (b) hereof in respect of any loss,
claim, damage or liability, or any action in respect thereof, then, in lieu of
the amount paid or payable under subsection (a) or (b) hereof, the indemnified

                                       9
<PAGE>

party and the indemnifying party under subsection (a) or (b) hereof shall
contribute to the aggregate losses, claims, damages and liabilities (including
legal or other expenses reasonably incurred in connection with investigating the
same), (i) in such proportion as is appropriate to reflect the relative fault of
the indemnifying party on the one hand, and the indemnified party on the other,
which resulted in such loss, claim, damage or liability, or action in respect
thereof, with respect to the statements or omissions which resulted in such
loss, claim, damage or liability, or action in respect thereof, as well as any
other relevant equitable considerations or (ii) if the allocation provided by
clause (i) above is not permitted by applicable law or if the allocation
provided in this clause (ii) provides a greater amount to the indemnified party
than clause (i) above, in such proportion as shall be appropriate to reflect not
only the relative fault but also the relative benefits received by the
indemnifying party and the indemnified party from the offering of the securities
covered by such registration statement as well as any other relevant equitable
considerations. The parties hereto agree that it would not be just and equitable
if contributions pursuant to this Section 2.5(d) were to be determined by pro
rata allocation or by any other method of allocation which does not take into
account the equitable considerations referred to in the preceding sentence of
this Section 2.5(d). No Person guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any Person who was not guilty of such fraudulent
misrepresentation. In addition, no Person shall be obligated to contribute
hereunder any amounts in payment for any settlement of any action or claim
effected without such Person's consent, which consent shall not be unreasonably
withheld or delayed. Notwithstanding anything in this subsection (d) to the
contrary, no indemnifying party (other than Stratagene) shall be required to
contribute any amount in excess of the proceeds (net of expenses and
underwriting discounts and commissions) received by such party from the sale of
the Registrable Securities in the offering to which the losses, claims, damages
or liabilities of the indemnified parties relate.

                  (e)      Other Indemnification. Indemnification and
contribution similar to that specified in the preceding subsections of this
Section 2.5 (with appropriate modifications) shall be given by Stratagene and
the Sorge Entities with respect to any required registration or other
qualification of securities under any Federal, state or blue sky law or
regulation of any governmental authority. The indemnification agreements
contained in this Section 2.5 shall be in addition to any other rights to
indemnification or contribution which any indemnified party may have pursuant to
law or contract and shall remain operative and in full force and effect
regardless of any investigation made by or on behalf of any indemnified party
and shall survive the transfer of any of the Registrable Securities by the Sorge
Entities.

                  (f)      Indemnification Payments. The indemnification and
contribution required by this Section 2.5 shall be made by periodic payments of
the amount thereof during the course of the investigation or defense, as and
when bills are received or expense, loss, damage or liability is incurred.

         2.6      Unlegended Certificates. In connection with the offering of
any Registrable Securities registered pursuant to this Section 2, Stratagene
shall (a) facilitate the timely preparation and delivery to Sorge and the
underwriters, if any, participating in such offering, of unlegended certificates
representing ownership of such Registrable Securities being sold in such
denominations and registered in such names as requested by Sorge or such
underwriters and (b) instruct any transfer agent and registrar of such
Registrable Securities to release any stop

                                       10
<PAGE>

transfer orders with respect to any such Registrable Securities, effective upon
the closing of a sale pursuant to the registered offering.

         2.7      No Required Sale. Nothing in this Agreement shall be deemed to
create an independent obligation on the part of the Sorge Entities to sell any
Registrable Securities pursuant to any effective registration statement.

         2.8      Rule 144. Stratagene shall use commercially reasonable efforts
to enable holders of Registrable Securities to sell such securities without
registration under the Securities Act within the limitation of the exemptions
provided by (a) Rule 144 of the Securities Act or (b) any similar rule or
regulation hereafter adopted by the SEC, including, without limiting the
generality of the foregoing, filing on a timely basis all reports required to be
filed by the Exchange Act. Upon the request of Sorge, Stratagene will deliver to
the Sorge Entities a written statement as to whether it has complied with such
requirements.

                                  ARTICLE III.
                                  MISCELLANEOUS

         3.1      Notice. All notices, requests, consents and other
communications hereunder to any party shall be deemed to be sufficient if
contained in a written instrument delivered in person or sent by telecopy,
nationally recognized overnight courier or first class registered or certified
mail, return receipt requested, postage prepaid, addressed to such party at such
address as set forth below or as may hereafter be designated in writing by such
party to the other party:

                  Address for Stratagene:

                           11011 North Torrey Pines Road
                           La Jolla, California 92037
                           Attention: Chief Financial Officer

                  Address for the Sorge Entities:

                           c/o Joseph A. Sorge
                           [Intentionally Omitted]

         3.2      Assignment; Third Party Beneficiaries. This Agreement shall be
binding upon and inure to the benefit of and be enforceable by the parties
hereto and their respective successors and permitted assigns. This Agreement may
not be assigned by Stratagene, without the prior written consent of Sorge. Each
of the Sorge Entities may, at their election, at any time or from time to time,
assign their rights under this Agreement, in whole or in part, but only to a
Permitted Transferee; provided that the Permitted Transferee shall be bound by
all provisions of this Agreement as if the Permitted Transferee were an original
party to this Agreement.

         3.3      Termination. This Agreement shall terminate and be of no
further force and effect on the earlier of (a) ten (10) years from the date of
this Agreement or (b) such time as no Registrable Securities are outstanding.
The Sorge Entities each represent and warrant to and

                                       11
<PAGE>

covenant with Stratagene that the Sorge Entities and their Affiliates will not
engage, directly or indirectly, in any short sales of the Common Stock prior to
the termination of this Agreement.

         3.4      Remedies. The parties hereto agree that money damages or any
other remedy at law would not be sufficient or adequate remedy for any breach or
violation of, or a default under, this Agreement by them and that, in addition
to all other remedies available to them, each of them shall be entitled to an
injunction restraining such breach, violation or default or threatened breach,
violation or default and to any other equitable relief, including, without
limitation, specific performance, without bond or other security being required.
In any action or proceeding brought to enforce any provision of this Agreement
(including the indemnification provisions thereof), the successful party shall
be entitled to recover reasonable attorneys' fees in addition to its costs and
expenses and any other available remedy.

         3.5      No Inconsistent Agreements. Stratagene will not, on or after
the date of this Agreement, enter into any agreement with respect to its
securities which is inconsistent with the rights granted to the Sorge Entities
in this Agreement or otherwise conflicts with the provisions hereof. Stratagene
further represents and warrants that the rights granted to the Sorge Entities
hereunder do not in any way conflict with and are not inconsistent with any
other agreements to which Stratagene is a party or by which it is bound.

         3.6      Amendments. The terms and provisions of this Agreement may be
modified or amended, or any of the provisions hereof waived, temporarily or
permanently, in a writing executed and delivered by Stratagene and Sorge.

         3.7      Waiver. No waiver of any of the provisions of this Agreement
shall be deemed to or shall constitute a waiver of any other provision hereof
(whether or not similar). No delay on the part of any party in exercising any
right, power or privilege hereunder shall operate as a waiver thereof.

         3.8      Headings. The headings of the sections of this Agreement have
been inserted for convenience of reference only and shall not be deemed to be a
part of this Agreement.

         3.9      Nouns and Pronouns. Whenever the context may require, any
pronouns used herein shall include the corresponding masculine, feminine or
neuter forms, and the singular form of names and pronouns shall include the
plural and vice versa.

         3.10     Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA WITHOUT GIVING
EFFECT TO THE PRINCIPLES OF CONFLICTS OF LAW.

         3.11     Submission to Jurisdiction. The parties hereto hereby
irrevocably and unconditionally consent to submit to the exclusive jurisdiction
of the courts of the State of California and of the United States of America, in
each case located in the County of San Diego, for any action or proceeding
arising out of or relating to this Agreement and the transactions contemplated
hereby (and agree not to commence any litigation relating hereto except in such
courts), and further agree that service of any process, summons, notice or
document by U.S. registered mail to its respective address shall be effective
service of process for any action or

                                       12
<PAGE>

proceeding brought against it in any such court. The parties hereto hereby
irrevocably and unconditionally (a) waive any objection to the laying of venue
of any action or proceeding arising out of this Agreement or the transactions
contemplated hereby in the courts of the State of California or the United
States of America, in each case located in the County of San Diego, and (b)
waive and agree not to plead or claim in any such court that any such action or
proceeding brought in any such court has been brought in an inconvenient forum.

         3.12     Waiver of Jury Trial. STRATAGENE AND THE SORGE ENTITIES HEREBY
WAIVE ANY RIGHT THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION OR
PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH
THIS AGREEMENT.

         3.13     Counterparts. This Agreement may be executed in any number of
counterparts, and each such counterpart hereof shall be deemed to be an original
instrument, but all such counterparts together shall constitute but one
agreement.

         3.14     Severability. Whenever possible, each provision of this
Agreement shall be interpreted in such manner as to be effective and valid, but
if any provision of this Agreement is held to be invalid or unenforceable in any
respect, such invalidity or unenforceability shall not render invalid or
unenforceable any other provision of this Agreement.

         3.15     Further Assurances. At any time or from time to time after the
date of this Agreement, Stratagene, on the one hand, and Sorge, on the other
hand, agree to cooperate with each other, and at the request of the other party,
to execute and deliver any further instruments or documents and to take all such
further action as the other party may reasonably request in order to evidence or
effectuate the consummation of the transactions contemplated hereby and to
otherwise carry out the intent of the parties hereunder.

         3.16     Entire Agreement; Effectiveness. This Agreement and the Merger
Agreement contain the entire agreement between the parties with respect to the
subject matter hereof and supersede all prior and contemporaneous arrangements
or understandings with respect thereto.

                            [Signature Page Follows]

                                       13
<PAGE>

                  IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be executed by their respective officers thereunto duly authorized
as of the day and year first above written.

                                    STRATAGENE:

                                    STRATAGENE CORPORATION,
                                    a Delaware corporation

                                    By:________________________________
                                    Name:
                                    Title:

                                    SORGE ENTITIES:

                                    JOSEPH A. SORGE

                                    By: ________________________________
                                        Joseph A. Sorge

                                    J. A. SORGE TRUST I

                                    By: ________________________________
                                        Joseph A. Sorge, Trustee

                                    J. A. SORGE TRUST II

                                    By: ________________________________
                                        Joseph A. Sorge, Trustee

                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]

<PAGE>

                                    J. A. SORGE TRUST III

                                    By: _________________________________
                                        Joseph A. Sorge, Trustee

                                    J. A. SORGE TRUST IV

                                    By: __________________________________
                                        Joseph A. Sorge, Trustee

                                    THE JOSEPH A. SORGE CHARITABLE
                                    REMAINDER TRUST DATED 12/26/02

                                    By: ___________________________________
                                        Joseph A. Sorge, Trustee

                                    BIOSENSE PARTNERS, L.P.

                                    By:  BIOSENSE MANAGEMENT, L.L.C.
                                    Its: General Partner

                                         By: ___________________________
                                         Name:  Joseph A. Sorge
                                         Title: Manager

                [SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]<PAGE>

                                                                    EXHIBIT 10.5

                              EMPLOYMENT AGREEMENT

                  THIS EMPLOYMENT AGREEMENT (the "Agreement") is made and
entered into as of September 4, 2001, by and between Stratagene Holding
Corporation, a Delaware corporation ("Employer"), and Nicholas H. Roelofs
("Executive").

                                    RECITALS

                  Employer wishes to exclusively contract for the managerial and
business skills possessed by Executive, and Executive desires to be employed by
Employer upon the terms and subject to the conditions herein provided.

                              TERMS AND CONDITIONS

                  NOW, THEREFORE, in consideration of the foregoing premises and
the mutual covenants and conditions hereinafter set forth, the parties hereto
agree as follows:

                                    ARTICLE I

                              EMPLOYMENT AND DUTIES

                  1.1      Position and Duties. Executive shall serve as Senior
Vice President of Marketing and Asian Sales, with responsibility for (i)
overseeing Employer's (and its affiliates) marketing and Asian sales functions
and (ii) such other duties as Employer's Chief Executive Officer or Board of
Directors may reasonably prescribe. Executive shall discharge his duties in a
diligent and professional manner. Further, Executive acknowledges and agrees
that Employer may at any time, or from time to time, modify the scope and/or
nature of the responsibilities, duties or reporting relationships of Executive.

                  1.2      Outside Business Activities Precluded. During his
employment, Executive shall devote his full energies, interest, abilities and
productive time to the performance of this Agreement. Executive shall not,
without the prior written consent of Employer, perform

                                       1

<PAGE>

other services of any kind or engage in any other business activity other than
for Employer (and its affiliated companies), with or without compensation.
Executive shall not, without the prior written consent of Employer, engage or
prepare to engage in any business activity adverse to Employer's interests.
Employer shall not unreasonably withhold its consent where the requested outside
activity does not detract from Executive's ability to devote his full energies,
interest, abilities and productive time to the performance of this Agreement and
does not adversely affect Employer's interests.

                                   ARTICLE II

                                  COMPENSATION

                  2.1      Salary. For Executive's services hereunder, Employer
shall pay as base salary to Executive the amount of $225,000 per year during the
Employment Term (as hereinafter defined), prorated for any year in which this
Agreement is in effect for only a portion of the calendar year. Said base salary
shall be payable in equal installments in conformity with Employer's normal
payroll period. Executive's salary shall be reviewed by Employer from time to
time at its discretion, and Executive shall receive such salary increases, if
any, as Employer, in its sole discretion, shall determine.

                  2.2      Other Benefits. During the Employment Term, Executive
shall be entitled to participate in and receive all other benefits of employment
generally available to Employer's other executive management personnel,
including, but not limited to, inclusion in Employer's retirement plan, medical
plan, disability plan and other similar benefit plans, subject to and on a basis
consistent with the terms, conditions and overall administration of such plans.
Executive shall be entitled to three weeks of paid vacation each year, which
will accrue and be paid out in conformity with Employer's normal vacation pay
practices. Employer may, in its sole discretion,

                                       2

<PAGE>

grant such additional benefits to Executive from time to time as Employer deems
proper and desirable.

                  2.3      Stock Options. Employer shall provide Executive with
stock options to purchase 75,000 shares of Employer's Common Stock at $6.00 per
share vesting in five equal installments of 15,000 stock options per each full
year of employment pursuant to a Non-Qualified Stock Option Agreement (the
"Non-Qualified Stock Option Agreement") to be executed by Employer and Executive
concurrently herewith in substantially the form attached hereto as Exhibit B.

                  2.4      Expenses. During the first year of the Employment
Term, Executive shall have access to an expense account in the amount of
$50,000, in accordance with the policies and procedures adopted from time to
time by Employer, provided that Executive properly accounts for such business
expenses in accordance with such policies and procedures.

                  2.5      Lock-up in Event of Initial Public Offering.
Executive agrees that, during a period of 180 days from the date of an initial
public offering of Employer's common stock, Executive will not, without the
prior written consent of the underwriter(s) of the initial public offering,
directly or indirectly, sell, offer to sell, grant any option or right for the
sale of, or otherwise dispose of or transfer, any shares of employer's common
stock.

                                   ARTICLE III

                               TERM OF EMPLOYMENT

                  3.1      At-Will Employment. Executive shall at all times be
an "at-will employee" of Employer. The term of this Agreement shall commence on
the date hereof and shall continue until terminated by either Employer or
Executive pursuant to Sections 3.2 through 3.6 of this Agreement, respectively
(the "Employment Term").

                                       3

<PAGE>

                  3.2      Early Termination by Employer. Executive's employment
may be terminated at any time during the Employment Term by the Chief Executive
Officer or Board of Directors of Employer, for any or no reason and without
Cause (as hereinafter defined), upon delivery of written notice by Employer.
Employer is not required to give Executive any advance notice of termination
which, in the sole discretion of Employer, may be effective immediately upon
delivery of written notice to Executive.

                  3.3      Early Termination by Executive. Executive may
terminate his employment under this Agreement at any time by giving Employer
written notice of his resignation thirty (30) days in advance; provided,
however, the Chief Executive Officer or Board of Directors of Employer may
determine upon receipt of such notice that the effective date of such
resignation shall be immediate or some time prior to the expiration of the
thirty-day (30) notice period.

                  3.4      Termination for Cause. Executive's employment may be
terminated for Cause by the Chief Executive Officer or Board of Directors of
Employer. For these purposes, termination for "Cause" shall mean termination
because of Executive's (a) personal dishonesty or willful material misconduct,
(b) failure to perform his duties or obligations, including failure to meet
deadlines or milestones, (c) committing embezzlement or a felony, or (d)
material breach of this Agreement or Employer's standard Employee Invention and
Proprietary Information Agreement.

                  3.5      Termination Due to Death or Disability. Executive's
employment hereunder shall terminate immediately upon his death. In the event
that by reason of injury, illness or other physical or mental impairment
Executive shall be (a) completely unable to perform his services hereunder for
more than one consecutive month or (b) unable to perform his

                                       4

<PAGE>

services hereunder for 50% or more of the normal working day throughout two
consecutive months, then Employer may terminate Executive's employment
hereunder. Executive's beneficiaries, estate, heirs, representatives or assigns,
as appropriate, shall be entitled to the proceeds, if any, due under any
Employer-paid life insurance policy held by Executive, as determined by and in
accordance with the terms of any such policy, as well as any vested benefits
such as accrued vacation benefits and stock options.

                                   ARTICLE IV

                    BENEFITS AFTER TERMINATION OF EMPLOYMENT

                  4.1      Continuation. Upon termination of employment under
this Agreement under Section 3.3 (Early Termination by Executive), Section 3.4
(Termination for Cause) or Section 3.5 (Termination Due to Death or Disability),
all salary and benefits of Executive hereunder shall cease immediately.
Executive's beneficiaries, estate, heirs, representatives or assigns, as
appropriate, shall be entitled to the proceeds, if any, due under any
Employer-paid life insurance policy held by Executive, as determined by and in
accordance with the terms of any such policy, as well as any vested benefits
such as accrued vacation benefits and stock options. Upon termination of
employment under this Agreement under Section 3.2 (Early Termination by
Employer) so long as Executive and Employer shall execute and deliver a mutual
general release in a form mutually acceptable in connection therewith, Executive
shall be entitled to receive payments in amounts equal to the continuation of
Executive's base salary for six (6) months from the date of termination;
provided, however, Employer's obligation to continue Executive's base salary
amount shall cease when Executive accepts employment or becomes eligible for
compensation (in the form of cash or securities), comparable to the base salary
provided to Executive hereunder, from some other source in exchange for
Executive's services. In no event,

                                       5

<PAGE>

however, shall Employer's obligation to Executive under this Section 4.1 exceed
an amount equal to Executive's base-salary for six (6) months minus any
compensation payable to Executive from some other source in exchange for
Executive's services during such six (6) month period. Except as expressly set
forth above, all unvested stock options, if any, granted to Executive shall
cease to vest and be exercisable upon any termination of this Agreement.

                  4.2      Rights Against Employer. The benefits payable under
this Article IV are exclusive, and no amount shall become payable to any person
(including Executive) by reason of termination of employment for any reason,
with or without Cause, except as provided in this Article IV and as described in
Section 3.5 (Termination Due to Death or Disability). Employer shall not be
obligated to segregate any of its assets or procure any investment in order to
fund the benefits payable under this Article IV.

                                    ARTICLE V

               CONFIDENTIAL INFORMATION AND CONFLICTS OF INTEREST

                  5.1      Employee Invention and Proprietary Information
Agreement. Employer and Executive shall execute concurrently herewith an
Employee Invention and Proprietary Information Agreement in substantially the
form attached hereto as Exhibit A.

                  5.2      Conflicts of Interest. Executive, while employed or
receiving severance payments hereunder, shall not take any action without
Employer's prior written consent to establish, form or become employed by
another business, other than interviewing with a prospective employer on
Executive's own time. Should Executive violate this provision, then in addition
to all other remedies Employer may have, Employer shall be entitled to
reimbursement from Executive for any benefits or compensation paid to Executive
under this Agreement on and after the date that Executive first breached this
provision.

                                       6

<PAGE>

                  5.3      General Responsibilities. Executive will be subject
to Employee's general employment policies and procedures which are described
from time to time in Employer's employee handbook which has been made available
to Executive. Employer may change or terminate the availability of any of the
benefits or responsibilities contained in such employee manual at any time or
from time to time in its sole discretion.

                                   ARTICLE VI

                               GENERAL PROVISIONS

                  6.1      Entire Agreement. This Agreement, the Employee
Invention and Proprietary Information Agreement, and the Non-Qualified Stock
Option Agreement contain the entire understanding and sole and entire agreement
between the parties with respect to the subject matter hereof and supersedes any
and all prior agreements, negotiations and discussions between the parties
hereto with respect to the subject matter covered hereby. Each party to this
Agreement acknowledges that no representations, inducements, promises or
agreements, oral or otherwise, have been made by any party, or anyone acting on
behalf of any party, which are not embodied herein, and that no other agreement,
statement or promise not contained in this Agreement shall be valid or binding.
This Agreement may not be modified or amended by oral agreement, but rather only
by an agreement in writing signed by Executive and the Chief Executive Officer
of Employer which specifically states the intent of the parties to amend this
Agreement.

                  6.2      Assignment and Binding Effect. Neither this Agreement
nor the rights or obligations hereunder shall be assignable by Executive.
Employer may assign this Agreement to any successor of Employer, and upon such
assignment any such successor shall be deemed substituted for Employer upon the
terms and subject to the conditions hereof.

                                       7

<PAGE>

                  6.3      Dispute Resolution. Any controversy or claim arising
out of or relating to this Agreement, or the breach thereof, that cannot be
resolved between the parties in a timely manner shall be resolved through final
and binding arbitration in San Diego, California in accordance with the
then-existing commercial arbitration rules (the "Rules") of the American
Arbitration Association ("AAA"), and judgement upon the award rendered by the
arbitrators may be entered in any court having competent jurisdiction thereof;
provided, however, that the law applicable to any controversy shall be the law
of the State of California, regardless of its or any other jurisdiction's choice
of law principles. Notwithstanding the above, nothing herein shall require
Employer to arbitrate any claim involving alleged breaches by Executive of his
duties to maintain the confidentiality of Employer's confidential or proprietary
information, including trade secrets, or to disclose and assign inventions to
Employer. Such claims may be the subject of a court action seeking legal or
equitable relief.

                  6.4      No Waiver. No waiver of any term, provision or
condition of this Agreement, whether by conduct or otherwise, in any one or more
instances shall be deemed or be construed as a further or continuing waiver of
any such term, provision or condition, or as a waiver of any other term,
provision or condition of this Agreement.

                  6.5      Governing Law; Rules of Construction. This Agreement
has been negotiated and executed in, and shall be governed by and construed in
accordance with the laws of, the State of California. Captions of the several
Articles and Sections of this Agreement are for convenience of reference only,
and shall not be considered or referred to in resolving questions of
interpretation with respect to this Agreement.

                  6.6      Notices. Any notice, request, demand or other
communication required or permitted hereunder shall be deemed to be properly
given when personally served in writing, or

                                       8

<PAGE>

when deposited in the United States mail, postage pre-paid, addressed to
Employer or Executive at his last-known address. Each party may change its
address by written notice in accordance with this Section.

                  Address for Employer:

                           Stratagene Holding Corporation
                           11011 North Torrey Pines Road
                           La Jolla, California  92037
                           Attention: Joseph A. Sorge, M.D.

                  Address for Executive:

                           Nicolas H. Roelofs, Ph.D.
                           [Intentionally Omitted]
                           [Intentionally Omitted]

                  6.7      Severability. The provisions of this Agreement are
severable. If any provision of this Agreement shall be held to be invalid or
otherwise unenforceable, in whole or in part, the remainder of the provisions or
enforceable parts hereof shall not be affected thereby and shall be enforced to
the fullest extent permitted by law.

                  6.8      Multiple Counterparts. This Agreement may be executed
in one or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.

               THE REMAINDER OF THIS PAGE LEFT BLANK INTENTIONALLY

                                       9

<PAGE>

                  IN WITNESS WHEREOF, this Agreement has been executed and
delivered by the parties hereto as of the date first above written.

                                      EMPLOYER:

                                      STRATAGENE HOLDING CORPORATION.

                                      By:        /s/ JOSEPH A SORGE, M.D.
                                          --------------------------------------
                                      Name:  Joseph A. Sorge, M.D.
                                      Title: Chief Executive Officer

                                      EXECUTIVE:

                                             /s/ NICOLAS H. ROELOFS, PH.D.
                                      ------------------------------------------
                                               Nicolas H. Roelofs, Ph.D.

                                      Address: [Intentionally Omitted]
                                               [Intentionally Omitted]

                                       10

<PAGE>

                                    EXHIBIT A

                             [INTENTIONALLY OMITTED]

<PAGE>

                                    EXHIBIT B

                             [INTENTIONALLY OMITTED]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}]]